Banff Centre Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2004
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Regulatory/Suppressor T Cells (D1)
Organizer(s) Ethan M. Shevach and Luciano Adorini
March 10—15, 2004
Banff Centre • Banff, Alberta Canada
Abstract Deadline: Nov 10, 2003
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 12, 2004
Sponsored in part by the Director's Sponsor Fund
Summary of Meeting:
Although the concept of suppression mediated by T lymphocytes was originally proposed more than 30 years ago, recent studies in animal models of autoimmunity have rekindled interest in the existence of a subset of lymphocytes that specifically suppress immune responses. One population of naturally-occurring or endogenous T suppressor cells can be identified by co-expression of the CD4 and CD25 antigens. These cells suppress the activation of CD4 and CD8 T cells in vitro by an unknown cell-contact dependent mechanism. In vivo, these cells suppress autoimmune disease by both cell contact-dependent and suppressor cytokine-dependent pathways. Although these cells were originally described in the mouse, a population with identical phenotypic and functional properties has been identified in man. A second group of suppressor cells can be induced in vivo by oral exposure to antigen, by culture of T cells with cytokines (IL-10), or by pharmacologic manipulation of dendritic cell functions. These antigen-induced suppressors primarily inhibit T cell activation in vitro and in vivo by secreting suppressor cytokines. Determination of the cellular target and the molecular basis of CD4+CD25+ mediated suppression is a major area of current research. The nature of the physiologic ligand recognized by these cells is also unknown as is the breadth of their T cell repertoire. Suppressor/regulatory T cells have primarily been shown to inhibit animal models of autoimmune disease. However, recent studies have extended their range of activities to inhibition of tumor immunity, graft rejection, allergic disease, graft versus host disease, and acute and chronic infectious diseases. One critical area of future study will involve the development of protocols to enhance regulatory T cell function in vivo by pharmacologic means as such an approach should prove useful in autoimmunity, allergic disease, and graft rejection. Similarly, a related area will involve inhibition of regulatory T cell function, either transiently or permanently, by pharmacologic manipulation or treatment of animals or man with monoclonal antibodies specific for effector molecules on these cells. Protocols are now being developed for the adoptive immunotherapy of both CD4+CD25+ T cells that have been expanded in vitro and for suppressor cells that have been induced in vitro. These cells will be administered to patients with GVHD, graft rejection, and organ-specific and systemic autoimmune disease. This meeting will review all of the above issues and focus on the manipulation of regulatory T cell function in animal models of human disease as well as in disease in man.
View Scholarships/Awards
Although the concept of suppression mediated by T lymphocytes was originally proposed more than 30 years ago, recent studies in animal models of autoimmunity have rekindled interest in the existence of a subset of lymphocytes that specifically suppress immune responses. One population of naturally-occurring or endogenous T suppressor cells can be identified by co-expression of the CD4 and CD25 antigens. These cells suppress the activation of CD4 and CD8 T cells in vitro by an unknown cell-contact dependent mechanism. In vivo, these cells suppress autoimmune disease by both cell contact-dependent and suppressor cytokine-dependent pathways. Although these cells were originally described in the mouse, a population with identical phenotypic and functional properties has been identified in man. A second group of suppressor cells can be induced in vivo by oral exposure to antigen, by culture of T cells with cytokines (IL-10), or by pharmacologic manipulation of dendritic cell functions. These antigen-induced suppressors primarily inhibit T cell activation in vitro and in vivo by secreting suppressor cytokines. Determination of the cellular target and the molecular basis of CD4+CD25+ mediated suppression is a major area of current research. The nature of the physiologic ligand recognized by these cells is also unknown as is the breadth of their T cell repertoire. Suppressor/regulatory T cells have primarily been shown to inhibit animal models of autoimmune disease. However, recent studies have extended their range of activities to inhibition of tumor immunity, graft rejection, allergic disease, graft versus host disease, and acute and chronic infectious diseases. One critical area of future study will involve the development of protocols to enhance regulatory T cell function in vivo by pharmacologic means as such an approach should prove useful in autoimmunity, allergic disease, and graft rejection. Similarly, a related area will involve inhibition of regulatory T cell function, either transiently or permanently, by pharmacologic manipulation or treatment of animals or man with monoclonal antibodies specific for effector molecules on these cells. Protocols are now being developed for the adoptive immunotherapy of both CD4+CD25+ T cells that have been expanded in vitro and for suppressor cells that have been induced in vitro. These cells will be administered to patients with GVHD, graft rejection, and organ-specific and systemic autoimmune disease. This meeting will review all of the above issues and focus on the manipulation of regulatory T cell function in animal models of human disease as well as in disease in man.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
WEDNESDAY, MARCH 10
THURSDAY, MARCH 11
FRIDAY, MARCH 12
SATURDAY, MARCH 13
SUNDAY, MARCH 14
MONDAY, MARCH 15
Conference Program Print | View meeting in 12 hr (am/pm) time
WEDNESDAY, MARCH 10
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Ethan M. Shevach,
NIAID, National Institutes of Health, USA
Ronald N. Germain,
NIAID, National Institutes of Health, USA
From Ts and I-J to Treg and CD25: From the Desert to the Promised Land?
From Ts and I-J to Treg and CD25: From the Desert to the Promised Land?
08:00—11:00
CD4+CD25+ T Cells: Properties and Function
Meeting has ended...abstracts no longer viewable online.
*
Shimon Sakaguchi,
Osaka University, Japan
Naturally Arising CD25+CD4+ Regulatory T Cells in Immunologic Tolerance: Foxp3, GiTR, IL-2/CO25 in Autoimmune Disease
Naturally Arising CD25+CD4+ Regulatory T Cells in Immunologic Tolerance: Foxp3, GiTR, IL-2/CO25 in Autoimmune Disease
Jocelyne Demengeot,
Instituto Gulbenkian de Ciencia, Portugal
Function and Dynamic of Regulatory T Cells during Inflammatory Responses
Function and Dynamic of Regulatory T Cells during Inflammatory Responses
Ethan M. Shevach,
NIAID, National Institutes of Health, USA
CD4+CD25+ T Cells: Regulating the Regulator
CD4+CD25+ T Cells: Regulating the Regulator
Brian R. Champion,
PsiOxus Therapeutics Ltd, UK
Peripheral T-Cell Regulation through the Notch Signaling Pathway
Peripheral T-Cell Regulation through the Notch Signaling Pathway
Dario A. A. Vignali,
University of Pittsburgh School of Medicine, USA
Short Talk: Role of LAG-3 in Regulatory T Cell Function
Short Talk: Role of LAG-3 in Regulatory T Cell Function
17:00—19:15
Induced Regulatory T Cells: Characterization and Function
Meeting has ended...abstracts no longer viewable online.
*
Maria Grazia Roncarolo,
Stanford University School of Medicine, USA
Mechanisms Underlying the Induction and Effector Function of Tr1 Cells
Mechanisms Underlying the Induction and Effector Function of Tr1 Cells
Luciano Adorini,
Intercept Pharmaceuticals, Inc., Italy
The Role of Dendritic Cells in the Induction of Regulatory T Cells
The Role of Dendritic Cells in the Induction of Regulatory T Cells
Richard A. Flavell,
HHMI/Yale University School of Medicine, USA
Regulation of the Autoimmune Response by Suppressor T Cells and Cytokines
Regulation of the Autoimmune Response by Suppressor T Cells and Cytokines
21:00—22:00
Workshop 1
*
Ethan M. Shevach,
NIAID, National Institutes of Health, USA
Xuguang Tai,
National Cancer Institute, National Institutes of Health, USA
Molecular Mapping of CD28 Costimulatory Signals Required for Treg Cell Generation
Molecular Mapping of CD28 Costimulatory Signals Required for Treg Cell Generation
Sylvain Fisson,
University of Evry Val d'Essonne, France
Homeostasis and Function of Islet Antigen-Specific Regulatory T Cells
Homeostasis and Function of Islet Antigen-Specific Regulatory T Cells
Mindi R. Walker,
Johnson and Johnson, USA
Induction of FoxP3 and Acquisition of T Regulatory Activity by Stimulated Human CD4+CD25- T Cells
Induction of FoxP3 and Acquisition of T Regulatory Activity by Stimulated Human CD4+CD25- T Cells
Shuang Liang,
University of Louisville Health Sciences Center, USA
CD4+CD25- Cells can be Converted into CD4+CD25+ Regulatory T Cells in the Periphery in the Absence of the Thymus
CD4+CD25- Cells can be Converted into CD4+CD25+ Regulatory T Cells in the Periphery in the Absence of the Thymus
Joerg Ermann,
Stanford University, USA
IL-2 Receptor Signaling in CD4+CD25+ Treg Cells
IL-2 Receptor Signaling in CD4+CD25+ Treg Cells
08:00—11:00
Induction and Maintenance of Regulatory T Cells
Meeting has ended...abstracts no longer viewable online.
Andrew Caton,
Wistar Institute, USA
CD4+ CD25+ Regulatory T Cell Selection
CD4+ CD25+ Regulatory T Cell Selection
*
Harald von Boehmer,
Harvard Medical School, USA
In vivo Lifestyle of Regulatory T Cells
In vivo Lifestyle of Regulatory T Cells
Thomas R. Malek,
University of Miami School of Medicine, USA
Role of IL-2 in the Production and Maintenance of T Regulatory Cells
Role of IL-2 in the Production and Maintenance of T Regulatory Cells
Marc A. Gavin,
Amgen, USA
Short Talk: A Role for Phosphodiesterase 3B in the Homeostasis of CD4+CD25+ Regulatory T Cells
Short Talk: A Role for Phosphodiesterase 3B in the Homeostasis of CD4+CD25+ Regulatory T Cells
17:00—19:00
CD8+ Regulatory T Cells
Meeting has ended...abstracts no longer viewable online.
Yong-Jun Liu,
Sanofi, USA
Human GITR-Ligand Preferentially Costimulate Cytotoxic CD8+ T Cells
Human GITR-Ligand Preferentially Costimulate Cytotoxic CD8+ T Cells
Nicole Suciu-Foca,
Columbia University, USA
CD8+CD28- Suppressor T Cells
CD8+CD28- Suppressor T Cells
Vipin Kumar,
Torrey Pines Institute for Molecular Studies, USA
A Novel, Non-Classical MHC-Restricted CD8+ Regulatory T Cell Population Prevents Experimental Autoimmune Encephalomyelitis
A Novel, Non-Classical MHC-Restricted CD8+ Regulatory T Cell Population Prevents Experimental Autoimmune Encephalomyelitis
Eli E. Sercarz,
Torrey Pines Institute for Molecular Studies, USA
Short Talk: The Optimal Targets for Regulatory T Cells Are Driver T Cell Clones
Short Talk: The Optimal Targets for Regulatory T Cells Are Driver T Cell Clones
21:00—22:00
Workshop 2
*
Ethan M. Shevach,
NIAID, National Institutes of Health, USA
Vivian Tseveleki,
Hellenic Pasteur Institute, Greece
Immunoregulatory Role of c-FLIPL in T Lymphocytes
Immunoregulatory Role of c-FLIPL in T Lymphocytes
Niklas Beyersdorf,
Institute for Virology and Immunobiology, Germany
Expansion and Activation of Rat CD4+CD25+ Regulatory T Cells by Superagonistic CD28-Specific Monoclonal Antibodies
Expansion and Activation of Rat CD4+CD25+ Regulatory T Cells by Superagonistic CD28-Specific Monoclonal Antibodies
Kerstin Siegmund,
Charité, Humboldt-Universitaet, Germany
Developmental Stage, Phenotype and Migration Distinguish Naïve- and Effector/Memory-Like CD4+ Regulatory T Cells
Developmental Stage, Phenotype and Migration Distinguish Naïve- and Effector/Memory-Like CD4+ Regulatory T Cells
Alistair Noble,
Rayne Institute, UK
CD8+, MHC Class I-Restricted Suppressor T Cells Secrete IFN-gamma and IL-10 but Act via Cell Contact Dependent Mechanisms
CD8+, MHC Class I-Restricted Suppressor T Cells Secrete IFN-gamma and IL-10 but Act via Cell Contact Dependent Mechanisms
Chyi-Song Hsieh,
Washington University, USA
Recognition of the Peripheral Self by Naturally-Arising CD25+ CD4+ T Cell Receptors
Recognition of the Peripheral Self by Naturally-Arising CD25+ CD4+ T Cell Receptors
08:00—11:00
Regulation of Immunity to Tumors and Infectious Agents
Meeting has ended...abstracts no longer viewable online.
Cornelis J. M. Melief,
Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Induction of Effective Tumor Immunity
Induction of Effective Tumor Immunity
Kingston H.G. Mills,
Trinity College Dublin, Ireland
T Cell Mediated Regulation of Immunity to Bacteria
T Cell Mediated Regulation of Immunity to Bacteria
Yasmine Belkaid,
NIAID, National Institutes of Health, USA
Regulatory T Cells Maintain Symbiosis between Immunity and Susceptibility to Parasite Infection
Regulatory T Cells Maintain Symbiosis between Immunity and Susceptibility to Parasite Infection
*
Matthias G. von Herrath,
Novo Nordisk and La Jolla Institute for Allergy and Immunology, USA
CD25+ Regulatory Cells in Viral Infections?
CD25+ Regulatory Cells in Viral Infections?
Weiping Zou,
University of Michigan, USA
Short Talk: Specific Recruitment of Regulatory T Cells Fosters Immune Privilege in Ovarian Carcinoma
Short Talk: Specific Recruitment of Regulatory T Cells Fosters Immune Privilege in Ovarian Carcinoma
17:00—19:00
Regulatory T Cells in Human Disease Session Sponsored in part by the National Multiple Sclerosis Society
Meeting has ended...abstracts no longer viewable online.
Alexander H. Enk,
Universitäts-Hautklinik Heidelberg, Germany
In vivo Function and Manipulation of Regulatory T Cells
In vivo Function and Manipulation of Regulatory T Cells
*
David A. Hafler,
Yale University School of Medicine, USA
CD4+CD25+ Regulatory T Cells are Altered in Patients with Multiple Sclerosis
CD4+CD25+ Regulatory T Cells are Altered in Patients with Multiple Sclerosis
Arne N. Akbar,
University College London, UK
Are Human CD4+CD25+ T Cells Derived From Effector Cells?
Are Human CD4+CD25+ T Cells Derived From Effector Cells?
Francesco Annunziato,
University of Florence, Italy
Short Talk: Effect of CD4+CD25+ or CD8+CD25+ FOXP3-Expressing Human T Regulatory Thymocytes on the Function of Autologous TH1 and TH2 Cells
Short Talk: Effect of CD4+CD25+ or CD8+CD25+ FOXP3-Expressing Human T Regulatory Thymocytes on the Function of Autologous TH1 and TH2 Cells
21:00—22:00
Workshop 3
*
Ethan M. Shevach,
NIAID, National Institutes of Health, USA
Salvatore Albani,
University of California, San Diego, USA
Epitope-Specific Immunotherapy Induces Immune Deviation of Pro-Inflammatory T Cells in Rheumatoid Arthritis
Epitope-Specific Immunotherapy Induces Immune Deviation of Pro-Inflammatory T Cells in Rheumatoid Arthritis
Claudia Mauri,
University College London, UK
The Generation and Function of Regulatory T Cells are Defective in Rheumatoid Arthritis: Reversal by Anti-TNFalpha Therapy
The Generation and Function of Regulatory T Cells are Defective in Rheumatoid Arthritis: Reversal by Anti-TNFalpha Therapy
Rong-Fu Wang,
Baylor College of Medicine, USA
Identification of Natural Ligands for Human CD4+ Regulatory T Cells: Implication for Immunotherapy
Identification of Natural Ligands for Human CD4+ Regulatory T Cells: Implication for Immunotherapy
Susmit Suvas,
Oakland University, USA
Role of CD4+CD25+ Regulatory T Cells in Herpes Viral Infection
Role of CD4+CD25+ Regulatory T Cells in Herpes Viral Infection
Robert N. Barker,
University of Aberdeen, UK
Immunosuppressive Regulatory T Cells in Hodgkin Lymphoma and Epstein-Barr Virus Infection
Immunosuppressive Regulatory T Cells in Hodgkin Lymphoma and Epstein-Barr Virus Infection
08:00—11:00
Regulatory T Cell in Autoimmunity Session Sponsored in part by the Juvenile Diabetes Research Foundation International
Meeting has ended...abstracts no longer viewable online.
Kenneth S. Tung,
University of Virginia, USA
Regional Lymph Node Regulation in 3dTx Mice
Regional Lymph Node Regulation in 3dTx Mice
*
Joan Goverman,
University of Washington, USA
Suppression of Myelin-Specific T Cells In Vivo
Suppression of Myelin-Specific T Cells In Vivo
Jeffrey A. Bluestone,
University of California, San Francisco, USA
Antigen-Specificity and Function of Regulatory T Cells
Antigen-Specificity and Function of Regulatory T Cells
Kristin V. Tarbell,
NIDDK, National Institutes of Health, USA
Short Talk: CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Block the Development of Diabetes in NOD Mice
Short Talk: CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Block the Development of Diabetes in NOD Mice
17:00—19:00
Regulatory T Cells in Transplantation and GVHD
Meeting has ended...abstracts no longer viewable online.
Kathryn J. Wood,
University of Oxford, UK
Manipulation of Regulatory T Cell Function in Transplantation
Manipulation of Regulatory T Cell Function in Transplantation
Bruce R. Blazar,
University of Minnesota, USA
The Role of CD4+CD25+ T Regulatory (Treg) Cells in Allogeneic Bone Marrow Transplantation (BMT)
The Role of CD4+CD25+ T Regulatory (Treg) Cells in Allogeneic Bone Marrow Transplantation (BMT)
*
Herman Waldmann,
University of Oxford, UK
Regulatory T Cells in Infectious Transplantion Tolerance
Regulatory T Cells in Infectious Transplantion Tolerance
Sergio A. Quezada,
University College London, UK
Short Talk: Visualizing Regulatory T Cell Control of Anti CD154-Induced Graft Tolerance in vivo
Short Talk: Visualizing Regulatory T Cell Control of Anti CD154-Induced Graft Tolerance in vivo
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
